Related references
Note: Only part of the references are listed.Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1?
Erica Giuliani et al.
CURRENT DRUG TARGETS (2016)
Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms
Jamie B. Spangler et al.
IMMUNITY (2015)
Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps
Suman Mitra et al.
IMMUNITY (2015)
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Alice Tzeng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Weiwen Deng et al.
SCIENCE (2015)
Perforin: structure, function, and role in human immunopathology
Ilia Voskoboinik et al.
IMMUNOLOGICAL REVIEWS (2015)
Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission
Jonathan E. Kolitz et al.
CANCER (2014)
Influence of natural killer cells and perforin-mediated cytolysis on the development of chemically induced lung cancer in A/J mice
Manuela Frese-Schaper et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Geok Choo Sim et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice
Katrin L. Gutbrodt et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Chimera of IL-2 Linked to Light Chain of anti-IL-2 mAb Mimics IL-2/anti-IL-2 mAb Complexes Both Structurally and Functionally
Jakub Tomala et al.
ACS CHEMICAL BIOLOGY (2013)
Regulation of Ligands for the NKG2D Activating Receptor
David H. Raulet et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2
Tania Carmenate et al.
JOURNAL OF IMMUNOLOGY (2013)
A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: A Cytokine Working Group (CWG) Study
Uday B. Dandamudi et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Crystal Structure of the Cowpox Virus-Encoded NKG2D Ligand OMCP
Eric Lazear et al.
JOURNAL OF VIROLOGY (2013)
Unique pulmonary antigen presentation may call for an alternative approach toward lung cancer immunotherapy
Stephanie Chang et al.
ONCOIMMUNOLOGY (2013)
New prospects on the NKG2D/NKG2DL system for oncology
Evelyn Ullrich et al.
ONCOIMMUNOLOGY (2013)
Strain-Specific Variation in Murine Natural Killer Gene Complex Contributes to Differences in Immunosurveillance for Urethane-Induced Lung Cancer
Daniel Kreisel et al.
CANCER RESEARCH (2012)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
Selectively Expanding Subsets of T Cells in Mice by Injection of Interleukin-2/Antibody Complexes: Implications for Transplantation Tolerance
O. Boyman et al.
TRANSPLANTATION PROCEEDINGS (2012)
Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
Claude Haan et al.
CHEMISTRY & BIOLOGY (2011)
Cancer Immunoediting of the NK Group 2D Ligand H60a
Timothy O'Sullivan et al.
JOURNAL OF IMMUNOLOGY (2011)
IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25
Sven Letourneau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
Carsten Krieg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
Brett H. Yamane et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma
A. Plonquet et al.
ANNALS OF ONCOLOGY (2007)
Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D
Jessica A. Campbell et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
Kim Margolin et al.
CLINICAL CANCER RESEARCH (2007)
DAP12 signaling directly augments proproliferative cytokine stimulation of NK cells during viral infections
Anthony R. French et al.
JOURNAL OF IMMUNOLOGY (2006)
Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics
Daniel B. Graham et al.
JOURNAL OF IMMUNOLOGY (2006)
Selective stimulation of T cell subsets with antibody-cytokine immune complexes
O Boyman et al.
SCIENCE (2006)
CD4+-CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
MJ Smyth et al.
JOURNAL OF IMMUNOLOGY (2006)
Roles of the NKG2D immunoreceptor and its ligands
DH Raulet
NATURE REVIEWS IMMUNOLOGY (2003)
Costimulation of multiple NK cell activation receptors by NKG2D
EL Ho et al.
JOURNAL OF IMMUNOLOGY (2002)
Recognition of a virus-encoded ligand by a natural killer cell activation receptor
HRC Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
UL16-Binding proteins, novel MHC class I-Related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells
CL Sutherland et al.
JOURNAL OF IMMUNOLOGY (2002)
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
K Imai et al.
LANCET (2000)
Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common gamma-chain and a lymphoid cell environment
AX Yu et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
